Medtronic's bifurcation stent starts human trial
This article was originally published in Clinica
A drug-eluting bifurcation stent could be on the horizon. Medtronic has initiated the first human trial of a non-drug-coated branched stent, results of which will determine whether it will begin developing a drug-eluting version. The safety and deliverability of the stent is being assessed in a 60-patient study called BRANCH, based in Australia and New Zealand. Primary endpoints include cardiac death, myocardial infarction involving the target vessel, and target vessel revascularisation (TVR) 30 days post-implant. Patient enrolment is expected to be complete by the end of 2008, with results available early in 2009.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.